Enterin Meets Study Endpoints for the Phase 2b (KARMET) Study Involving Patients With Parkinson's Disease
January 27, 2022 09:00 ET
|
Enterin Inc.
PHILADELPHIA, Jan. 27, 2022 (GLOBE NEWSWIRE) -- Enterin Inc., a privately held, Philadelphia-based, clinical-stage biopharmaceutical company pioneering novel treatments for neurodegenerative and...
Enterin to Announce Top-Line Results From the Phase 2b Study for Parkinson's Disease
January 25, 2022 09:00 ET
|
Enterin Inc.
PHILADELPHIA, Jan. 25, 2022 (GLOBE NEWSWIRE) -- Enterin Inc., a privately held, Philadelphia-based, clinical-stage biopharmaceutical company pioneering novel treatments for neurodegenerative and...
Enterin Announces Appointment of Dr. Patrik Brundin to Its Scientific Advisory Board
January 10, 2022 09:00 ET
|
Enterin Inc.
PHILADELPHIA, Jan. 10, 2022 (GLOBE NEWSWIRE) -- Enterin Inc., a privately held, Philadelphia-based, clinical-stage biopharmaceutical company pioneering novel treatments for neurodegenerative and...
Enterin Announces Publication of Exciting Discoveries About the Enterin Nervous System
November 19, 2021 09:00 ET
|
Enterin Inc.
PHILADELPHIA, Nov. 19, 2021 (GLOBE NEWSWIRE) -- Enterin Inc., a privately held Philadelphia-based clinical-stage biopharmaceutical company pioneering novel treatments for neurodegenerative and...
Enterin Announces Appointment of Dr. Roger Mills to Its Board of Directors
September 13, 2021 09:00 ET
|
Enterin Inc.
PHILADELPHIA, Sept. 13, 2021 (GLOBE NEWSWIRE) -- Enterin, Inc., a privately held, Philadelphia-based, clinical-stage biopharmaceutical company pioneering novel treatments for neurodegenerative and...